Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Houssein Ayoub and Ali Latif.
Houssein Ayoub
Connection Strength
0.823
Ali Latif
  1. Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: mathematical modelling analyses. BMJ Innov. 2021 Apr; 7(2):327-336.
    View in: PubMed
    Score: 0.234
  2. Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19. J Glob Health. 2021 Jan 16; 11:05005.
    View in: PubMed
    Score: 0.231
  3. Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. J Travel Med. 2021 10 11; 28(7).
    View in: PubMed
    Score: 0.061
  4. Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting. Clin Infect Dis. 2021 10 05; 73(7):e1830-e1840.
    View in: PubMed
    Score: 0.061
  5. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021 09; 27(9):1614-1621.
    View in: PubMed
    Score: 0.060
  6. Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar. Emerg Infect Dis. 2021 05; 27(5):1343-1352.
    View in: PubMed
    Score: 0.059
  7. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. EClinicalMedicine. 2021 May; 35:100861.
    View in: PubMed
    Score: 0.059
  8. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. Sci Rep. 2021 03 18; 11(1):6233.
    View in: PubMed
    Score: 0.058
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.